GLI1 and hematologic disorder: In addition, the FDA-approved GLI1/GLI2 inhibitor Arsenic-trioxide (ATO), is currently under phase I/IV clinical trials for various solid and hematological malignancies [41, 42] and therefore, warrants further evaluation in combination with other key signaling pathways inhibitors for therapy of the HH-driven tumors such as MB.